Rapid normalization of alanine aminotransferase predicts viral response during combined peginterferon and ribavirin treatment in chronic hepatitis C patients
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: The treatment for chronic hepatitis C (CHC) is removal of the virus in order to prevent progression to liver cirrhosis and hepatocellular carcinoma (HCC). Few data have been presented regarding the clinical significance of changes in the alanine aminotransferase (ALT) level in this context. We analyzed the patterns of changes in ALT level and investigated the relationship between the rapid normalization of ALT and sustained virologic response (SVR) after combined treatment with peginterferon and ribavirin. Methods: CHC patients (n=370) were classified into four groups according to the initial ALT level and subsequent changes: (1) initially abnormal ALT level and sustained abnormal ALT level during treatment, (2) initially abnormal ALT level but achievement of ALT normalization, (3) initially normal ALT level and variable ALT abnormality during treatment, and (4) initially normal ALT level and sustained normalization of ALT level during treatment. We subdivided groups 1 and 2 into those with patterns of decreased and normalization of ALT, with or without rapid normalization. We checked the end-treatment response (ETR) and SVR rates in each group and the factors associated with SVR, including patterns of changes in ALT level. Results: A total of 168 patients completed the therapy (age=54.34±10.64 years [mean±SD], 95 males [56.5%], genotype 1:82 [48.8%]). SVR was achieved in 115 (68.45%) of the completely treated patients. The SVR rate was significantly lower in group 1 than in group 2 (37.8 vs. 81.6%,P<0.001), and significantly higher in the rapid normalization group than in the group without rapid normalization (78.5%vs. 41.2%, P<0.001). Multiple logistic regression analysis revealed that age (odds ratio [OR]=0.94, 95% confidence interval [CI]=0.91-0.98, P=0.005), viral genotype (OR=2.76, 95% CI=1.20-6.38, P=0.017), and initial hepatitis C virus RNA titer (OR=0.28, 95% CI=0.10-0.75, P=0.012) were identified as independent significant predictive factors for SVR. Conclusions: The SVR rate is significantly associated with normalization, and especially rapid normalization of ALT. Rapid normalization of ALT by 4 weeks after treatment might be a useful response factor that is readily available in clinical practice, and especially for genotype 1 patients. (Korean J Hepatol 2012;18:41-47)
Abstract
Background/Aims: The treatment for chronic hepatitis C (CHC) is removal of the virus in order to prevent progression to liver cirrhosis and hepatocellular carcinoma (HCC). Few data have been presented regarding the clinical significance of changes in the alanine aminotransferase (ALT) level in this context. We analyzed the patterns of changes in ALT level and investigated the relationship between the rapid normalization of ALT and sustained virologic response (SVR) after combined treatment with peginterferon and ribavirin. Methods: CHC patients (n=370) were classified into four groups according to the initial ALT level and subsequent changes: (1) initially abnormal ALT level and sustained abnormal ALT level during treatment, (2) initially abnormal ALT level but achievement of ALT normalization, (3) initially normal ALT level and variable ALT abnormality during treatment, and (4) initially normal ALT level and sustained normalization of ALT level during treatment. We subdivided groups 1 and 2 into those with patterns of decreased and normalization of ALT, with or without rapid normalization. We checked the end-treatment response (ETR) and SVR rates in each group and the factors associated with SVR, including patterns of changes in ALT level. Results: A total of 168 patients completed the therapy (age=54.34±10.64 years [mean±SD], 95 males [56.5%], genotype 1:82 [48.8%]). SVR was achieved in 115 (68.45%) of the completely treated patients. The SVR rate was significantly lower in group 1 than in group 2 (37.8 vs. 81.6%,P<0.001), and significantly higher in the rapid normalization group than in the group without rapid normalization (78.5%vs. 41.2%, P<0.001). Multiple logistic regression analysis revealed that age (odds ratio [OR]=0.94, 95% confidence interval [CI]=0.91-0.98, P=0.005), viral genotype (OR=2.76, 95% CI=1.20-6.38, P=0.017), and initial hepatitis C virus RNA titer (OR=0.28, 95% CI=0.10-0.75, P=0.012) were identified as independent significant predictive factors for SVR. Conclusions: The SVR rate is significantly associated with normalization, and especially rapid normalization of ALT. Rapid normalization of ALT by 4 weeks after treatment might be a useful response factor that is readily available in clinical practice, and especially for genotype 1 patients. (Korean J Hepatol 2012;18:41-47)
참고문헌 (17)
- Tong MJ, "Evidence for hepatitis C viral infection in patients with primary hepatocellular carcinoma", West J Med, 160, pp.133~138 (1994)
- Lee SS, "Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)", J Hepatol, 37, pp.500~506 (2002)
- Ferenci P, "Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)", ribavirin, 2005, pp.43, 425~433
- Wai CT, "A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C", Hepatology, 38, pp.518~526 (2003)
- Lim YS, "Current status of liver disease in Korea: hepatitis C", Korean J Hepatol, 15(Suppl 6), pp.S25~S28 (2009)
- Hung CH, "Is delayed normalization of alanine aminotransferase a poor prognostic predictor in chronic hepatitis C patients treated with a combined interferon and ribavirin therapy?", J Gastroenterol Hepatol, 17, pp.1307~1311 (2002)
- Tong MJ, "Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison", Hepatology, 26, pp.1640~1645 (1997)
- Yamada G, "Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level", Hepatology, 22, pp.1351~1354 (1995)
- Hoofnagle JH, "Course and outcome of hepatitis C", Hepatology, 36(Suppl 1), pp.S21~S29 (2002)
- Puoti C, "Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels", Hepatology, 26, pp.1393~1398 (1997)
- Davis GL, "Clinical predictors of response to recombinant interferon-alpha treatment in patients with chronic non-A, non-B hepatitis (hepatitis C). The Hepatitis Interventional Therapy Group", J Viral Hepat, 1, pp.55~63 (1994)
- Civeira MP, "Early predictors of response to treatment in patients with chronic hepatitis C", J Hepatol, 31(Suppl 1), pp.237~243 (1999)
- Zeuzem S, "Peginterferon alfa-2a in patients with chronic hepatitis C", N Engl J Med, 343, pp.1666~1672 (2000)
- 정승원, "만성 C형간염에서 페그인터페론과 리바비린의 병합치료 시 지속바이러스반응에 대한 순응도의 효과", Clinical and Molecular Hepatology, 15(3), pp.338~349 (2009), 대한간학회
- Davis GL, "Factors predictive of a beneficial response to therapy of hepatitis C", Hepatology, 26(Suppl 1), pp.122S~127S (1997)
- Blatt LM, "Discordance between serum alanine aminotransferase (ALT) and virologic response to IFN-alpha2b in chronic hepatitis C patients with high and low pretreatment serum hepatitis C virus RNA titers", J Interferon Cytokine Res, 18, pp.75~80 (1998)
- Basso M, "Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA-negative patients are associated with virological relapse", Hepatology, 49, pp.1442~1448 (2009)